Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
about
New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases.Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.Is autoimmunity the Achilles' heel of cancer immunotherapy?Pembrolizumab use for the treatment of advanced melanoma.Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials.Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer.Thyroid dysfunctions secondary to cancer immunotherapy.Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature.Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics.Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.Endocrinopathies with use of cancer immunotherapies.Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer.Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.Immune-Related Thyroiditis with Immune Checkpoint InhibitorsThe Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
P2860
Q33564645-0E1A6BA4-AD45-48B3-9251-63D9834C2913Q33650208-36857966-6D28-4D93-816A-B7625A9BC178Q37713503-A20C3704-D61A-4306-853D-E5D82233141FQ38687375-46A838AE-D035-4372-9E3E-66CC37283F0EQ39190201-3AD23D8B-C67B-44B4-9842-A099F3899A21Q39369955-60CD0895-78D6-4CE8-985C-3B452FA7A103Q39441719-76F0E7A3-B0F9-4614-A9D5-7666C5897A77Q42370605-4FBFD4EE-30F7-4110-A03F-4A887CAC71D0Q47106542-334A7F5A-27ED-4376-95D3-8BED1FBB6C83Q47236362-AD07F8BF-D9E8-4E5D-A88E-22009D0E421EQ47565857-E553B4CE-5FCF-4AEB-83D4-3E46BAEE1E3AQ47825909-38C58D63-247D-4824-B337-7837DCBADCC7Q47906372-98A2D27E-D345-4275-BD3F-039F8316FF8FQ48277793-56C628D5-4463-40BC-8B4C-4674AD483F68Q48289680-74E149EC-FB38-4AFD-8554-E220A3A95B3AQ48300545-72D8F55C-4379-4751-82CC-AC0597D327DDQ50086190-E4BB2A4C-F3E0-4884-B38F-C746F3900E70Q50203400-0E750612-0DA4-4EFA-A3A7-7C21DD2368BBQ55207190-FC12781C-7962-4409-9A63-FB5CA9691D44Q55311366-22A3FB05-79F5-4C27-AE20-454B2A26E9E0Q55384189-4F65AF3A-90C2-4A31-92D8-91298BE9DD80Q55385874-31D7C146-C1CD-4399-8389-98DEBDF79E2EQ57146198-E965D416-26DE-422F-B73E-472C776CAF7DQ57178624-154F4625-7B65-4FA6-B942-910F47473ED5
P2860
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Incidence of Thyroid-Related A ...... ts Treated With Pembrolizumab.
@en
Incidence of Thyroid-Related A ...... ts Treated With Pembrolizumab.
@nl
type
label
Incidence of Thyroid-Related A ...... ts Treated With Pembrolizumab.
@en
Incidence of Thyroid-Related A ...... ts Treated With Pembrolizumab.
@nl
prefLabel
Incidence of Thyroid-Related A ...... ts Treated With Pembrolizumab.
@en
Incidence of Thyroid-Related A ...... ts Treated With Pembrolizumab.
@nl
P2093
P2860
P356
P1476
Incidence of Thyroid-Related A ...... ts Treated With Pembrolizumab.
@en
P2093
Bert Bravenboer
Brigitte Velkeniers
Hendrik Everaert
Max Schreuer
Yanina Jansen
P2860
P304
P356
10.1210/JC.2016-2300
P407
P577
2016-08-29T00:00:00Z